117969-88-7 (2-氨基-4-羟基-5-氟嘧啶,2-Pyrimidinol,4-amino-5-fluoro-)

(9ci)-4-氨基-5-氟-2-羟基嘧啶;2-氨基-4-羟基-5-氟嘧啶;2-氨基-4-羟基-5-氟嘧啶 1G;

2-Pyrimidinol,4-amino-5-fluoro-;2-Pyrimidinol, 4-amino-5-fluoro- (9CI);6-Amino-5-fluoro-2(1H)-pyrimidinone;C4H4FN3O;Flucytosine 100 microg/mL in Acetonitrile:Water;NS00000532;SR-01000721885;HMS3393M04;5-Fluorocytosin;AC-11748;Ro-2-9915;CCG-213434;SMR000059047;FLUCYTOSINE (MART.);HSDB 3082;HMS2097L10;FLUCYTOSINE [MI];BPBio1_000956;FLUCYTOSINE [ORANGE BOOK];NSC-103805;Fluorcytosine;Flucytosine (USAN:USP:INN:BAN:JAN);CHEBI:5100;Flucitosina;2-Hydroxy-4-amino-5-fluoropyrimidine;4-amino-5-fluoropyrimidin-2-ol;130256-61-0;Flucytosone;BDBM50248003;6-amino-5-fluoro-3-hydropyrimidin-2-one;5-Flucytosine;1LD;WLN: T6MVNJ DZ EF;AKOS004912683;SCHEMBL24063;FLUCYTOSINE [INN];Prestwick0_000934;2(1H)-Pyrimidinone, 4-amino-5-fluoro-);D00323;5-Fluorocytosine, Antibiotic for Culture Media Use Only;MFCD00006035;CAS-2022-85-7;Flucytosine,(S);NC00087;Alcobon;BSPBio_000868;HMS3655G17;AM20090149;6-amino-5-fluoropyrimidin-2(1H)-one;6-Amino-2-oxo-5-fluoropyrimidine;4-AMINO-2-HYDROXY-5-FLUOROPYRIMIDINE;NSC 103805;5-Fluorocytosine, Vetec(TM) reagent grade, 99%;FLUCYTOSINE [EP MONOGRAPH];EMTRICITABINE IMPURITY E;HMS1570L10;FT-0601273;Flucytosine (Ancobon);Flucytosinum (INN-Latin);AB00444223-16;SPBio_003037;Flucytosine, United States Pharmacopeia (USP) Reference Standard;SB57097;MLS000069463;4-amino-5-fluoro-1,2-dihydropyrimidin-2-one;HMS2093J05;flucytosine;4-Amino-5-fluoro-2-hyroxypyrimidine;Opera_ID_178;s1666;flucytosina;BP-30254;SY004438;Ancobon (TN);5-fluorocytosine Form I;FLUCYTOSINE [WHO-IP];HY-B0139;HMS2051M04;SW197278-3;FLUCYTOSINE (EP MONOGRAPH);NCGC00016599-05;2(1H)-Pyrimidinone, 6-amino-5-fluoro-;FLUCYTOSINE [JAN];BCP9000692;A814346;FLUCYTOSINE [USP MONOGRAPH];4-Amino-5-fluoro-1H-pyrimidin-2-one;EN300-117264;Flucytosine [USAN:USP:INN:BAN:JAN];FLUCYTOSINE (USP IMPURITY);MLS000759519;CS-1935;UNII-D83282DT06;Flucytosinum;5-fluoro-cytosine;BCP0726000281;Flucytosine, European Pharmacopoeia (EP) Reference Standard;4-AMINO-5-FLUOROPYRIMIDIN-2(1H)-ONE [WHO-IP];EMTRICITABINE IMPURITY E [WHO-IP];Flucytosine, Pharmaceutical Secondary Standard; Certified Reference Material;2(1H)-Pyrimidinone, 4-amino-5-fluoro-;KS-1060;MLS001424013;Flucytosine, 5-Fluorocytosine;FLUCYTOSINE [MART.];6-amino-5-fluoro-1H-pyrimidin-2-one;Flucitosina [DCIT];NSC-759130;117969-88-7;FLUCYTOSINE [USP IMPURITY];Q238490;Cytosine, 5-fluoro-;NSC103805;FLUCYTOSINE (USP MONOGRAPH);Flucytosine 2.0 mg/ml in Methanol;HMS3373L05;ST028644;F-3010;NCGC00016599-01;FLUCYTOSINE [USAN];Tox21_110515;6-amino-5-fluoro-2(1H)-pyrimidinone;5-FLUOROCYTOSINE;NSC759130;Prestwick2_000934;Flucytosine (JP17/USP/INN);5-fluoro cytosine;Z1201621875;4-amino-5-fluoro-pyrimidin-2-ol;MLS001076503;AB00513969-02;HMS3714L10;ALA-ALA-PHEP-NITROANILIDE;Flucytosine [USAN);FLUCYTOSINE (USP-RS);5-FLUORO-4-IMINO-1,2,3,4-TETRAHYDROPYRIMIDIN-2-ONE;4-Amino-5-fluoropyrimidin-2(1H)-one;Flucytosinum [INN-Latin];5-Flurocytosine;EINECS 217-968-7;Flucytosine for system suitability;5-Fluorocystosine;BRD-K82143716-001-15-7;CCG-100837;NCGC00016599-04;HMS2233I14;D01AE21;5-Fluorocytosine;Flucytosin;AKOS030241326;GS-5578;EC 217-968-7;Prestwick3_000934;Ancoban;DTXCID403059;FLUCYTOSINE [USP-RS];DB01099;4-Amino-5-fluoro-2(1H)-pyrimidinone;F0321;5-fluorocytosine Form II;Ancobon;4-Amino-5-fluoro-2-hydroxypyrimidine;Flucytosinum (Latin);Cytosine, 5-fluoro- (6CI,7CI,8CI);FLUCYTOSINUM [WHO-IP LATIN];FLUCYTOSINE [WHO-DD];Fluocytosine;5-FLUOROCYTOSINE [WHO-IP];Ancotil;Ro 29915 E/265601;Ro 2-9915;Flourocytosine;2022-85-7;AB00513969_04;2-Pyrimidinol, 4-amino-5-fluoro-;D83282DT06;BCP02877;5-fluorocytocine;6-amino-5-fluoro-1,2-dihydropyrimidin-2-one;SR-01000721885-5;CPD000059047;DTXSID3023059;Ancotyl;H10295;J02AX01;Fluorocytosine;Prestwick1_000934;NCI60_000093;AB00513969;FLUCYTOSINE [HSDB];CHEMBL1463;5-Fluorocytosine (5-FC);4-AMINO-5-FLUORO-2(1H)-PYRIMIDINE;Flucytosine for system suitability, European Pharmacopoeia (EP) Reference Standard;Ro-29915;AKOS015896898;SCHEMBL14696800;FT-0695664;5-FC;Pharmakon1600-01505429;AKOS005063821;NCGC00016599-02;AB00513969_03;Tox21_110515_1;

XRECTZIEBJDKEO-UHFFFAOYSA-N

1S/C4H4FN3O/c5-2-1-7-4(9)8-3(2)6/h1H,(H3,6,7,8,9)

FC1C=NC(NC=1N)=O

主要用于皮肤黏膜念珠菌病、念珠菌心内膜炎、念珠菌关节炎、隐球菌脑膜炎和着色真菌病。抗真菌药。

1.由5-氟尿嘧啶经氯化、氨化、水解而得。1.氯化将5-氟尿嘧啶和三氯氧磷加入氯化锅,搅拌,控制在20℃以下滴加N,N-二甲基苯胺。滴加完毕,升温到110℃左右反应2h。冷至室温,放至冰盐水中冰解,维持15℃搅拌1h。过滤,水洗,得2,4-二氯-5-氟嘧啶。2.氨化将2,4-二氯-5-氟嘧啶溶解在乙醇中,搅拌,控制在35℃以下滴加氨水。滴毕,降温至25℃反应3h,减压回收乙醇至干,加水搅拌升温到20℃。过滤,用水洗涤结晶,干燥,得出4-氨基-2-氯-5-氟嘧啶。...